Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Benz

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Toxicology Mechanisms and Methods|December 22, 2009
In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property DescriptorsJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Advanced Drug Delivery Reviews|January 19, 2007
Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated productsNaomi L Kruhlak, Joseph F Contrera, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|August 21, 2007
Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR modelsJoseph F Contrera, Naomi L Kruhlak, Edwin J Matthews, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial dataEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Clinical Anatomy (New York, N.Y.)|April 28, 2015
Morphology of the humeral insertion of the supraspinatus and infraspinatus tendons: Application to rotator cuff repairWilliam Lumsdaine, Adam Smith, Rowan G Walker, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modelingEdwin J Matthews, Naomi L Kruhlak, James L Weaver, et al.
Regulatory Toxicology and Pharmacology : RTP|December 15, 2005
An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methodsEdwin J Matthews, Naomi L Kruhlak, Michael C Cimino, et al.
Regulatory Toxicology and Pharmacology : RTP|January 3, 2006
An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpointsEdwin J Matthews, Naomi L Kruhlak, Michael C Cimino, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2006
A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicalsEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Molecular Nutrition & Food Research|December 22, 2009
Testing computational toxicology models with phytochemicalsLuis G Valerio, Kirk B Arvidson, Emily Busta, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Toxicology Mechanisms and Methods|December 22, 2009
In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property DescriptorsJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Advanced Drug Delivery Reviews|January 19, 2007
Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated productsNaomi L Kruhlak, Joseph F Contrera, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|August 21, 2007
Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR modelsJoseph F Contrera, Naomi L Kruhlak, Edwin J Matthews, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial dataEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Clinical Anatomy (New York, N.Y.)|April 28, 2015
Morphology of the humeral insertion of the supraspinatus and infraspinatus tendons: Application to rotator cuff repairWilliam Lumsdaine, Adam Smith, Rowan G Walker, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modelingEdwin J Matthews, Naomi L Kruhlak, James L Weaver, et al.
Regulatory Toxicology and Pharmacology : RTP|December 15, 2005
An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methodsEdwin J Matthews, Naomi L Kruhlak, Michael C Cimino, et al.
Regulatory Toxicology and Pharmacology : RTP|January 3, 2006
An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpointsEdwin J Matthews, Naomi L Kruhlak, Michael C Cimino, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2006
A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicalsEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Molecular Nutrition & Food Research|December 22, 2009
Testing computational toxicology models with phytochemicalsLuis G Valerio, Kirk B Arvidson, Emily Busta, et al.
Pageof 4